|
A revolution is taking place in the Big-Pharma industry, as they increasingly search externally for innovative technologies to replenish their pipelines. All the major companies are prioritising engagement and partnering with start-up and early stage R&D companies with a view to securing the very best technologies to augment their own research.
For small companies, partnership with these big players not only offers a source of funding, but also helps them tap into a broader competency base of therapeutic, drug development, regulatory submission, and commercialisation expertise. Nearly one third of new life science products are now developed through alliances.
BioTrinity has always been the premier environment for putting small R&D companies together with a full range of international funders, including angels, VC's, corporates, patient capital, and specialist crowd-funders.
Now, Big-Pharma is essentially competing against these 'traditional' funding sources to secure your collaboration, giving small R&D companies increased leverage and a broader range of opportunities and choice than ever before.
BioTrinity is highlighting this trend in a panel entitled 'Pharma Licensing - Pros and Cons of early stage collaboration / partnering with Big Pharma' where we will explore the benefits of early stage pharma collaboration, verses 'keeping your powder dry' and potentially having a wider range of options downstream.
A huge range of Big-Pharma representatives are anxious to meet with you at BioTrinity, with event sponsorship by Abbvie, Lilly, BMS, Takeda, Pfizer, GSK, MSD, and Sanofi. This is an unrivalled opportunity to interact with all the major players under one roof.
Partnering opens on the 20th March, so ensure you optimise your chances of meeting exactly who you want to see by registering in advance at www.biotrinty.com and gaining pole position for meeting requests. There are also still some places left to showcase your company to the assembled investors and Big Pharma partnering attendees.
|
